

Supplementary figure 1 Hospital sample and patient record flowchart

Supplementary table 1 Thromboembolic risk stratification used. Based on ACCP 2012 guideline [13]

	VKA indication		
Risk stratum	**Mechanical heart valve**	**Atrial fibrillation**	**Venous thromboembolism (VTE)**
High	**Any mitral valve prosthesis** **Any caged-ball or tilting disk aortic valve prosthesis** **iCVA or TIA within 6 months** **Previous thromboembolic event during VKA interruption**	**CHA_2DS_2-VASC score 8 or 9** **iCVA or TIA within 3 months** **CHA_2DS_2-VASC score <8 with iCVA or TIA >3 months ago** **Rheumatic valvular heart disease** **Previous thromboembolic event during VKA interruption**	**VTE within 3 months** **Severe thrombophilia (e.g. deficiency of protein C or S or anti-thrombin, anti-phospholipid antibodies; multiple abnormalities)** **Previous thromboembolic event during VKA interruption**
Moderate	**Bileaflet aortic valve prosthesis and one or more riskfactors:** • **Atrial fibrillation** • **iCVA or TIA** • **Hypertension** • **Diabetes** • **Heart failure** • **Age >75 years**	**CHA_2DS_2-VASC score 5 to 7**	**VTE within the past 3-12 months** **Recurrent VTE** **Non-severe thrombophilia (e.g. heterozygous factor V or prothrombin gene mutation)** **Active cancer**
Low	**Bileaflet aortic valve without riskfactors**	**CHA_2DS_2-VASC score <5**	**VTE > 12 months and no other risk factors**

CHA_2DS_2-VASC= Congestive heart failure, hypertension, age ≥75, diabetes, iCVA/TIA, vascular disease; iCVA: ischaemic cerebrovascular accident; TIA: transient ischaemic attack

Supplementary table 2 LMWH dose thresholds used for sub therapeutic and therapeutic dose classification. Based on the Dutch antithrombotic policy guideline [31]

LMWH	Sub therapeutic dose threshold	Weight adjusted therapeutic dose threshold
Dalteparin	**> 5.000 IE/day**	**< 55 kg: ≥ 10.000 IE/day** **≥ 55 < 65 kg: ≥ 12.500 IE/day** **≥ 65 < 85 kg: ≥ 15.000 IE/day** **≥ 85 kg: ≥ 18.000 IE/day**
Nadroparin	**> 5.700 IE/day**	**< 50 kg: ≥ 7.600 IE/day** **≥ 50 < 70 kg: ≥ 11.400 IE/day** **≥ 70 < 90 kg: ≥ 15.200 IE/day** **≥ 90 kg: ≥ 19.000 IE/day**
Tinzaparin	**> 4.500 IE/day**	**< 60 kg: ≥ 10.000 IE/day** **≥ 60 < 80 kg: ≥ 14.000 IE/day** **≥ 80 kg: ≥ 18.000 IE/day**

Supplementary table 3 Use of postoperative bridging anticoagulation regimen for patients' bodyweight groups

	Postoperative bridging anticoagulation regimen [a]		
	Sub therapeutic dose N=54	Therapeutic dose N=45	*P-value* [b]
Patient bodyweight (kg), n (%)			<.001
< 50	0 (0)	3 (100)	
50-70	5 (23.8)	16 (76.2)	
70-90	27 (58.7)	19 (41.3)	
>90	22 (75.9)	7 (24.1)	

[a] Excluding patients who received both therapeutic and intermediate doses (n=4) and patients with unknown doses (n=4)

[b] Fisher's exact test